Search

Boehringer Ingelheim and Click Therapeutics Expand their Existing Collaboration to Develop Prescription Digital Therapeutics for Schizophrenia

SPEVIGO approved for expanded indications in China and the US

FDA approval for the Treatment of Generalized Pustular Psoriasis (GPP) in Adults and Pediatric Patients 12 Years of Age and Older Weighing at Least 40kg

Boehringer Ingelheim and Zealand Pharma Receive FDA Fast Track Designation for Investigational Treatment for NASH

Boehringer Ingelheim acquires Abexxa Biologics to further expand its research efforts in cancer immunology and novel immunotherapeutic approaches

Boehringer Ingelheim and King’s College London join forces to progress new therapeutic concepts in major depressive disorder and schizophrenia

She finds purpose in the saddle and pursues a passion for horses – at home and work

Boehringer Ingelheim and Zealand Pharma Advance Dual-Acting GLP-1/glucagon Agonist BI 456906 to Phase 2 Clinical Testing in Obesity/Diabetes

Boehringer Ingelheim and the Atlanta Humane Society mark the grand opening of a unique pet adoption center in Metro Atlanta

Boehringer Ingelheim and Vanderbilt University Announce Partnership to Develop Novel Therapies for Psychiatric Disorders

Boehringer Ingelheim and University of Dundee Highlight Successful PROTAC Drug Discovery Program and Extend Their Ongoing Anti-Cancer Alliance

FDA Approves Pradaxa® (dabigatran etexilate mesylate) for Treatment and Reduction in the Risk of Recurrence of Deep Venous Thrombosis and Pulmonary Embolism

Boehringer Ingelheim and Vanderbilt University join forces to develop new Ras inhibitors for cancer treatment

Boehringer Ingelheim and Vanderbilt University join forces

Accessibility Statement

Boehringer Ingelheim endeavors to make https://www.boehringer-ingelheim.com accessible to any and all users.

First Patient Enrolled in New Cardiovascular and Renal Outcomes Trial for TRADJENTA® (linagliptin) Tablets in Type 2 Diabetes

Icahn School of Medicine at Mount Sinai and Boehringer Ingelheim collaborate on first study to evaluate nintedanib in patients with fibrosing ILD following COVID-19 infection

About Us

Click here to discover more about Boehringer Ingelheim and our headquarters and largest U.S subsidiary in Connecticut.

New retrospective data showed empagliflozin reduced A1C, body weight and markers of abdominal fat in adults with type 2 diabetes

U.S. FDA Approves Once-daily Jentadueto® XR (linagliptin and metformin hydrochloride extended-release) Tablets for Adults with Type 2 Diabetes

Jardiance associated with a total cost of care savings of more than 20%, according to results from an outcomes-based agreement between Boehringer Ingelheim and Highmark

Boehringer Ingelheim and Lilly announce the CAROLINA cardiovascular outcome trial of Tradjenta met its primary endpoint of non-inferiority compared with glimepiride

Jardiance® reduced risk of cardiovascular death in adults with type 2 diabetes and peripheral artery disease

Boehringer Ingelheim and Lilly announce an academic collaboration with University of Oxford to investigate the effects of Jardiance® in adults with chronic kidney disease

Jardiance® reduced risk of kidney disease progression in adults with type 2 diabetes and established cardiovascular (CV) disease independent of control of conventional CV risk factors

Click here to read more about how the use of JARDIANCE reduced the risk of kidney disease progression in adults with established CVD and T2D.

New analysis estimates the positive impact of Jardiance® on life expectancy in adults with type 2 diabetes and established cardiovascular disease

Jardiance® Recommended as Preferred SGLT2 Inhibitor for Adults with Type 2 Diabetes and Established Cardiovascular Disease in American College of Cardiology Expert Consensus Decision Pathway

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers

Search

Boehringer Ingelheim and Click Therapeutics Expand their Existing Collaboration to Develop Prescription Digital Therapeutics for Schizophrenia

SPEVIGO approved for expanded indications in China and the US

Boehringer Ingelheim and Zealand Pharma Receive FDA Fast Track Designation for Investigational Treatment for NASH

Boehringer Ingelheim acquires Abexxa Biologics to further expand its research efforts in cancer immunology and novel immunotherapeutic approaches

Boehringer Ingelheim and King’s College London join forces to progress new therapeutic concepts in major depressive disorder and schizophrenia

She finds purpose in the saddle and pursues a passion for horses – at home and work

Boehringer Ingelheim and Zealand Pharma Advance Dual-Acting GLP-1/glucagon Agonist BI 456906 to Phase 2 Clinical Testing in Obesity/Diabetes

Boehringer Ingelheim and the Atlanta Humane Society mark the grand opening of a unique pet adoption center in Metro Atlanta

Boehringer Ingelheim and Vanderbilt University Announce Partnership to Develop Novel Therapies for Psychiatric Disorders

Boehringer Ingelheim and University of Dundee Highlight Successful PROTAC Drug Discovery Program and Extend Their Ongoing Anti-Cancer Alliance

FDA Approves Pradaxa® (dabigatran etexilate mesylate) for Treatment and Reduction in the Risk of Recurrence of Deep Venous Thrombosis and Pulmonary Embolism

Boehringer Ingelheim and Vanderbilt University join forces to develop new Ras inhibitors for cancer treatment

Accessibility Statement

First Patient Enrolled in New Cardiovascular and Renal Outcomes Trial for TRADJENTA® (linagliptin) Tablets in Type 2 Diabetes

Icahn School of Medicine at Mount Sinai and Boehringer Ingelheim collaborate on first study to evaluate nintedanib in patients with fibrosing ILD following COVID-19 infection

About Us

New retrospective data showed empagliflozin reduced A1C, body weight and markers of abdominal fat in adults with type 2 diabetes

U.S. FDA Approves Once-daily Jentadueto® XR (linagliptin and metformin hydrochloride extended-release) Tablets for Adults with Type 2 Diabetes

Jardiance associated with a total cost of care savings of more than 20%, according to results from an outcomes-based agreement between Boehringer Ingelheim and Highmark

Boehringer Ingelheim and Lilly announce the CAROLINA cardiovascular outcome trial of Tradjenta met its primary endpoint of non-inferiority compared with glimepiride

Jardiance® reduced risk of cardiovascular death in adults with type 2 diabetes and peripheral artery disease

Boehringer Ingelheim and Lilly announce an academic collaboration with University of Oxford to investigate the effects of Jardiance® in adults with chronic kidney disease

Jardiance® reduced risk of kidney disease progression in adults with type 2 diabetes and established cardiovascular (CV) disease independent of control of conventional CV risk factors

New analysis estimates the positive impact of Jardiance® on life expectancy in adults with type 2 diabetes and established cardiovascular disease

Jardiance® Recommended as Preferred SGLT2 Inhibitor for Adults with Type 2 Diabetes and Established Cardiovascular Disease in American College of Cardiology Expert Consensus Decision Pathway